
Sinovac Publishes Positive Data on its Covid Vaccine
Chinese biotech Sinovac has published data from the Phase 1/2 trial with its Covid-19 vaccine candidate in the journal Lancet Infectious Diseases. The results are said to show that the candidate is capable of inducing a quick antibody response within four weeks of immunization if given in two doses at a 14-day interval.